Payment overview · 2025
General Payments
$271.34
14 reported records · 7 companies
Healthcare provider profile · identity verified
Raquel Appa Falcao, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MECHANICSVILLE, VA · NPI 1114219839
Verified facts
What the public records show
CMS Open Payments records show Raquel Appa Falcao, MD received $271.34 in general payments during 2025 across 14 reported records.
Abbott Laboratories accounted for 31.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $85.44 | 31.5% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $48.36 | 17.8% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $39.08 | 14.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.24 | 11.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.18 | 10.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.26 | 8.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.78 | 5.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $271.34 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $85.44 | 4 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $39.08 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $31.51 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $30.24 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.18 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $29.18 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $23.26 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.26 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.78 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 90 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 74 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
74 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
90 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 385 | 116 |
| Atorvastatin Calcium | Atorvastatin Calcium | 379 | 111 |
| Levothyroxine Sodium | Levothyroxine Sodium | 223 | 66 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 205 | 62 |
| Lisinopril | Lisinopril | 197 | 60 |
| Gabapentin | Gabapentin | 195 | 46 |
| Losartan Potassium | Losartan Potassium | 189 | 58 |
| Metformin Hcl Er | Metformin Hcl | 155 | 47 |
| Famotidine | Famotidine | 154 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 137 | 41 |
| Metformin Hcl | Metformin Hcl | 126 | 32 |
| Trazodone Hcl | Trazodone Hcl | 119 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 117 | 37 |
| Omeprazole | Omeprazole | 113 | 38 |
| Furosemide | Furosemide | 105 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 105 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 99 | 30 |
| Eliquis | Apixaban | 90 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 85 | 35 |
| Simvastatin | Simvastatin | 81 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 17 |
| Pregabalin | Pregabalin | 76 | 27 |
| Sertraline Hcl | Sertraline Hcl | 75 | 21 |
| Ozempic | Semaglutide | 74 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 22 |
| Alprazolam | Alprazolam | 71 | 20 |
| Tramadol Hcl | Tramadol Hcl | 69 | 14 |
| Carvedilol | Carvedilol | 68 | 24 |
| Ezetimibe | Ezetimibe | 67 | 18 |
| Montelukast Sodium | Montelukast Sodium | 67 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 67 | 14 |
| Jardiance | Empagliflozin | 59 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 57 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 51 | 28 |
| Buspirone Hcl | Buspirone Hcl | 51 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 17 |
| Potassium Chloride | Potassium Chloride | 51 | 13 |
| Lorazepam | Lorazepam | 50 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 48 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | 14 |
| Mirtazapine | Mirtazapine | 42 | 13 |
| Prednisone | Prednisone | 40 | 26 |
| Chlorthalidone | Chlorthalidone | 39 | suppressed |
| Ondansetron Odt | Ondansetron | 39 | suppressed |
| Atenolol | Atenolol | 38 | suppressed |
| Bupropion Xl | Bupropion Hcl | 37 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | suppressed |
| Clonazepam | Clonazepam | 36 | suppressed |
| Spironolactone | Spironolactone | 36 | 13 |
| Alendronate Sodium | Alendronate Sodium | 34 | suppressed |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Glipizide | Glipizide | 33 | suppressed |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Baclofen | Baclofen | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 32 | suppressed |
| Valsartan | Valsartan | 32 | 11 |
| Allopurinol | Allopurinol | 31 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 30 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 29 | 11 |
| Nystatin | Nystatin | 29 | 16 |
| Fluconazole | Fluconazole | 28 | 11 |
| Meloxicam | Meloxicam | 26 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 14 |
| Klor-Con M20 | Potassium Chloride | 24 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Belsomra | Suvorexant | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 12 |
| Glipizide Er | Glipizide | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Trulance | Plecanatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $271.34 · 14 records | Abbott Laboratories | Dexcom G6 Transmitter, ELIQUIS, EVENITY, FREESTYLE LIBRE 3, INSPIRE, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, UBRELVY | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error